XHKG
9933
Market cap211mUSD
Dec 05, Last price
1.74HKD
1D
1.75%
1Q
-15.53%
IPO
419.40%
Name
GHW International
Chart & Performance
P/E
117.13
P/S
0.39
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
4.71%
Rev. gr., 5y
14.46%
Revenues
3.86b
+20.02%
Net income
13m
+368.17%
CFO
61m
-49.17%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GHW International, an investment holding company, manufactures and sells chemical and pharmaceutical products in the People's Republic of China, Europe, Vietnam, rest of Asia, and internationally. It operates through four segments: Polyurethane Materials, Animal Nutrition Chemicals, Fine Chemicals, and Pharmaceutical Products and Intermediates. The Polyurethane Materials segment offers polymeric methylene diphenyl diisocyanate and toluene diisocyanate, and polymer polyether for use in cushion foams, interior components, and other lightweight automotive parts. The Animal Nutrition Chemicals segment provides choline chloride and betaine used in feeds for poultry and livestock. The Fine Chemicals segment offers carboxylic acids, solvents, resins, and oleochemicals used in the paint and synthesis of dyes, production of lubricants, emulsifiers, cosmetics, flavors and fragrances, and feed additives. The Pharmaceutical Products and Intermediates segment produces and sells isooctanoic acid and diethyl sulfate for use in paint drier, fungicide, preservative and pharmaceutical raw materials, synthesis of dyes, pesticides, and pharmaceutical intermediates; and iodine and iodine derivatives, and pharmaceutical products, such as cefpodoxime dispersible tablets. GHW International was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||